Profile data is unavailable for this security.
About the company
Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company focused on the development of gene therapies for rare and devastating diseases. The Company has two clinical stage and one pre-clinical stage in vivo adeno-associated viral (AAV) programs in the United States, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is the most common form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart resulting in enlarged heart chambers that are unable to pump blood.
- Revenue in USD (TTM)0.00
- Net income in USD-223.12m
- Incorporated1999
- Employees202.00
- LocationRocket Pharmaceuticals Inc9 Cedarbrook DriveCRANBURY 08512United StatesUSA
- Phone+1 (646) 440-9100
- Fax+1 (781) 676-2155
- Websitehttps://www.rocketpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kyverna Therapeutics Inc | 0.00 | -160.99m | 486.15m | 129.00 | -- | 2.45 | -- | -- | -3.72 | -3.72 | 0.00 | 3.47 | 0.00 | -- | -- | 0.00 | -61.17 | -- | -69.77 | -- | -- | -- | -- | -- | -- | -- | 0.0013 | -- | -- | -- | -111.17 | -- | -- | -- |
| Prothena Corporation PLC | 9.68m | -244.09m | 506.03m | 67.00 | -- | 1.80 | -- | 52.25 | -4.53 | -4.53 | 0.1799 | 5.21 | 0.0222 | -- | -- | 144,537.30 | -55.86 | -19.16 | -62.22 | -20.73 | -- | -- | -2,520.57 | -114.82 | -- | -- | 0.00 | -- | -92.84 | 62.56 | -99.57 | -- | -6.78 | -- |
| Lyell Immunopharma Inc | 41.00k | -325.66m | 511.98m | 300.00 | -- | 1.41 | -- | 12,487.30 | -22.26 | -22.26 | 0.0027 | 17.06 | 0.00008 | -- | -- | 136.67 | -63.41 | -28.62 | -67.72 | -30.08 | -- | -- | -794,292.70 | -1,176.84 | -- | -- | 0.00 | -- | -53.08 | -37.83 | -46.18 | -- | 14.67 | -- |
| ADC Therapeutics SA | 75.21m | -166.94m | 517.81m | 263.00 | -- | -- | -- | 6.88 | -1.51 | -1.51 | 0.6852 | -2.11 | 0.2355 | 0.3207 | 3.20 | 285,965.80 | -52.26 | -45.95 | -65.58 | -53.58 | 92.73 | -- | -221.97 | -263.96 | 4.34 | -2.91 | 2.10 | -- | 1.84 | 97.79 | 34.25 | -- | -16.59 | -- |
| Fulcrum Therapeutics Inc | 0.00 | -74.88m | 520.15m | 55.00 | -- | 1.49 | -- | -- | -1.18 | -1.18 | 0.00 | 5.24 | 0.00 | -- | -- | 0.00 | -23.89 | -30.35 | -24.84 | -32.48 | -- | -- | -- | -344.07 | -- | -- | 0.00 | -- | -100.00 | -- | -669.97 | -- | -25.21 | -- |
| Lexeo Therapeutics Inc | 0.00 | -104.97m | 520.40m | 72.00 | -- | 3.24 | -- | -- | -2.70 | -2.70 | 0.00 | 2.20 | 0.00 | -- | -- | 0.00 | -66.08 | -- | -76.72 | -- | -- | -- | -- | -- | -- | -- | 0.0084 | -- | -- | -- | -48.11 | -- | -- | -- |
| Neumora Therapeutics Inc | 0.00 | -236.30m | 527.34m | 95.00 | -- | 3.92 | -- | -- | -1.46 | -1.46 | 0.00 | 0.8161 | 0.00 | -- | -- | 0.00 | -89.11 | -55.45 | -99.96 | -58.77 | -- | -- | -- | -- | -- | -- | 0.1289 | -- | -- | -- | -3.33 | -- | -- | -- |
| Rocket Pharmaceuticals Inc | 0.00 | -223.12m | 539.59m | 202.00 | -- | 1.94 | -- | -- | -2.01 | -2.01 | 0.00 | 2.56 | 0.00 | -- | -- | 0.00 | -52.00 | -42.96 | -56.68 | -46.18 | -- | -- | -- | -- | -- | -- | 0.0713 | -- | -- | -- | 13.77 | -- | -56.75 | -- |
| Larimar Therapeutics Inc | 0.00 | -132.00m | 541.78m | 65.00 | -- | 3.22 | -- | -- | -1.93 | -1.93 | 0.00 | 1.62 | 0.00 | -- | -- | 0.00 | -64.96 | -45.05 | -76.53 | -50.22 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -118.15 | -- | -7.58 | -- |
| Contineum Therapeutics Inc | 0.00 | -59.39m | 560.36m | 41.00 | -- | 2.48 | -- | -- | -2.26 | -2.26 | 0.00 | 6.18 | 0.00 | -- | -- | 0.00 | -29.19 | -- | -30.09 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -285.99 | -- | -- | -- |
| Design Therapeutics Inc | 0.00 | -67.45m | 582.74m | 55.00 | -- | 2.92 | -- | -- | -1.19 | -1.19 | 0.00 | 3.51 | 0.00 | -- | -- | 0.00 | -28.49 | -18.88 | -29.66 | -19.44 | -- | -- | -- | -98,925.22 | -- | -- | 0.00 | -- | -- | -- | 25.84 | -- | -- | -- |
| Zura Bio Ltd | 0.00 | -62.52m | 582.83m | 30.00 | -- | 4.06 | -- | -- | -0.6686 | -0.6686 | 0.00 | 1.66 | 0.00 | -- | -- | 0.00 | -39.10 | -- | -49.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 34.45 | -- | -- | -- |
| Replimune Group Inc | 0.00 | -314.85m | 591.22m | 479.00 | -- | 2.71 | -- | -- | -3.44 | -3.44 | 0.00 | 2.64 | 0.00 | -- | -- | 0.00 | -67.19 | -33.04 | -75.03 | -35.07 | -- | -- | -- | -- | -- | -- | 0.2565 | -- | -- | -- | -14.60 | -- | 0.4456 | -- |
| Allogene Therapeutics Inc | 0.00 | -212.02m | 595.53m | 226.00 | -- | 1.88 | -- | -- | -0.981 | -0.981 | 0.00 | 1.41 | 0.00 | -- | -- | 0.00 | -41.21 | -31.11 | -43.96 | -33.14 | -- | -- | -- | -1,187.06 | -- | -- | 0.00 | -- | -76.84 | -- | 21.29 | -- | -57.62 | -- |
Data as of Mar 03 2026. Currency figures normalised to Rocket Pharmaceuticals Inc's reporting currency: US Dollar USD
49.90%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RTW Investments LPas of 31 Dec 2025 | 17.69m | 16.34% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 7.95m | 7.34% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 6.50m | 6.01% |
| Citigroup Global Markets, Inc. (Investment Management)as of 31 Dec 2025 | 5.25m | 4.85% |
| Suvretta Capital Management LLCas of 31 Dec 2025 | 2.99m | 2.77% |
| Monaco Asset Management SAMas of 31 Dec 2025 | 2.99m | 2.76% |
| Morgan Stanley & Co. LLCas of 31 Dec 2025 | 2.84m | 2.62% |
| Newtyn Management LLCas of 31 Dec 2025 | 2.65m | 2.45% |
| D. E. Shaw & Co. LPas of 31 Dec 2025 | 2.64m | 2.44% |
| Maverick Capital Ltd.as of 31 Dec 2025 | 2.51m | 2.32% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
